Kiniksa Pharmaceuticals International, plc· KNSA
🇺🇸 US · MidBroad USNASDAQ
- Price
- $73.41
- Day
- -1.25%
- Mkt Cap
- $5.59B
- 52W Range
- $31.78 – $82.94
- Volume
- 785.3K
- Beta
- 0.07
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.